The @FDA.gov approved the targeted therapy belzutifan with the immunotherapy pembrolizumab, administered intravenously or subcutaneously, for certain adults with clear cell renal cell carcinoma at intermediate-high or high-risk following surgery: buff.ly/UpWY6AS
www.fda.gov
On June 12, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and…
